Federated Hermes
ARQT icon

Federated Hermes’s Arcutis Biotherapeutics ARQT Stock Holding History

Federated Hermes’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.5M Buy
1,124,629
+47,362
+4% +$1.1M 0.04% 386
2026
Q1 		$25.4M Buy
1,077,267
+185,500
+21% +$4.73M 0.04% 413
2025
Q4 		$25.9M Buy
891,767
+132,194
+17% +$3.38M 0.04% 395
2025
Q3 		$14.3M Buy
759,573
+22,204
+3% +$350K 0.03% 484
2025
Q2 		$10.3M Sell
737,369
-186
-0% -$2.61K 0.02% 566
2025
Q1 		$11.5M Buy
737,555
+244,633
+50% +$3.45M 0.02% 527
2024
Q4 		$6.87M Sell
492,922
-8,909
-2% -$97.6K 0.02% 635
2024
Q3 		$4.67M Buy
501,831
+151,717
+43% +$1.5M 0.01% 729
2024
Q2 		$3.26M Hold
350,114
– – 0.01% 812
2024
Q1 		$3.47M Sell
350,114
-171,355
-33% -$1.28M 0.01% 805
2023
Q4 		$1.68M Buy
521,469
+461,469
+769% +$1.25M ﹤0.01% 1000
2023
Q3 		$319K Buy
60,000
+20,000
+50% +$170K ﹤0.01% 1453
2023
Q2 		$381K Buy
40,000
+10,000
+33% +$111K ﹤0.01% 1449
2023
Q1 		$330K Buy
30,000
+6,000
+25% +$86.8K ﹤0.01% 1504
2022
Q4 		$355K Buy
+24,000
New +$419K ﹤0.01% 1442

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Federated Hermes's ARQT Position: Q2 2026 in Review

Federated Hermes increased its Arcutis Biotherapeutics (ARQT) stake by 4.4% in Q2 2026, buying an estimated $1.1M and bringing the position to 1,124,629 shares worth $29.5M. The position accounts for 0.04% of the portfolio, ranked #386.

Federated Hermes first reported a position in ARQT in Q4 2022 and has held it in 15 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Federated Hermes held 1,124,629 shares of Arcutis Biotherapeutics worth $29.5M as of Q2 2026.
  • Federated Hermes bought 47,362 Arcutis Biotherapeutics shares in Q2 2026, an estimated $1.1M.
  • Arcutis Biotherapeutics made up 0.04% of Federated Hermes's portfolio in Q2 2026, its #386 holding.
  • Federated Hermes first reported a position in Arcutis Biotherapeutics in Q4 2022 and has held it in 15 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.